TwoStep Therapeutics

Developing tumor-targeted therapies with broad applicability across solid tumors

Redefining targeted cancer therapy

shortfall

Backed by

science

How TwoStep's targeting molecule works, and where it's headed

Building the future of targeted therapy

Updates from TwoStep

September 2026

Exclusive: Cancer biotech TwoStep gets $62.5M to take twist on ADCs into clinic

Read article

September 2026

TwoStep Therapeutics Announces Oversubscribed $62.5 Million Series A Financing and FDA Clearance of IND for First-in-Class Peptide-Drug Conjugate

Read article

July 2026

TwoStep Therapeutics to Present at the Targeted Radiopharmaceuticals Summit 2026

Read article